Navigating Treatment Sequencing in HER2+ Metastatic Breast Cancer: Evidence-Based Approaches

EP. 1: Clinical Scenario I: 52-year-old Woman With Recurrent Metastatic HER2+ Breast Cancer

April 30th 2025

Panelists discuss how a 52-year-old elementary school teacher diagnosed with HER2-positive (HER2+) breast cancer achieved pathologic complete response with neoadjuvant therapy but experienced metastasis 18 months after completing treatment, requiring first-line metastatic therapy.

EP. 2: Clinical Insights Into Treatment Approach for Metastatic HER+ mBC Patient Case

April 30th 2025

Panelists discuss how they approach treatment sequencing for HER2-positive (HER2+) metastatic breast cancer (mBC) after progression on first-line therapy, including considerations for trastuzumab deruxtecan and the impressive results from the PATINA trial adding CDK4/6 inhibitors to maintenance therapy.

EP. 3: Expert Perspectives on Navigating Treatment-Related Adverse Events With T-DXd

May 7th 2025

Panelists discuss how they manage adverse effects of trastuzumab deruxtecan (T-DXd), particularly focusing on nausea, fatigue, and the critical monitoring needed for interstitial lung disease (ILD), with recommendations for prophylactic antiemetics and frequent imaging.

EP. 4: Managing Brain Metastases in HER2+ Breast Cancer: Second-Line Treatment Decisions

May 7th 2025

Panelists discuss how the presence of brain metastases influences treatment decisions in HER2-positive (HER2+) breast cancer, highlighting the DESTINY-Breast12 trial demonstrating trastuzumab deruxtecan’s (T-DXd) efficacy in patients with brain metastases.

EP. 5: Forty-Seven-Year-Old Woman With Recurrent HER2+ Breast Cancer and Brain Metastases

May 14th 2025

Panelists discuss how they approach the case of a 47-year-old marketing executive with initially low-risk HER2-positive (HER2+) breast cancer who developed brain, liver, lung, and bone metastases shortly after completing adjuvant therapy.

EP. 6: Clinical Insights on the Next Treatment Approach for Metastatic HER2+ Breast Cancer with Brain Metastasis

May 14th 2025

Panelists discuss how they would approach multiple brain metastases at initial metastatic diagnosis, debating the use of stereotactic radiosurgery vs systemic therapy with agents that cross the blood-brain barrier.

EP. 7: Navigating Third-Line Treatment Options in HER2+ Breast Cancer: ADC or TKI

May 21st 2025

Panelists discuss how National Comprehensive Cancer Network (NCCN) guidelines inform third-line treatment options for HER2-positive (HER2+) metastatic breast cancer, with particular focus on the HER2CLIMB regimen (tucatinib, capecitabine, and trastuzumab) for patients with brain metastases.

EP. 8: Tucatinib Combinations in HER2+ Breast Cancer: HER2CLIMB-02 and HER2CLIMB-05

May 21st 2025

Panelists discuss how the HER2CLIMB-02 and HER2CLIMB-05 trials might impact treatment sequencing, with particular interest in using tucatinib earlier in treatment to potentially prevent brain metastases.

EP. 9: Balancing Efficacy and Tolerability: Expert Insights Into Tucatinib Triplet Therapy for HER2+ Breast Cancer

May 28th 2025

Panelists discuss how they manage adverse effects of tucatinib-based therapy, particularly focusing on diarrhea and palmar-plantar erythrodysesthesia from capecitabine, with practical dosing strategies to improve tolerability.

EP. 10: Clinical Insights Into Managing Heavily Pretreated HER2+ Metastatic Breast Cancer

May 28th 2025

Panelists discuss how they approach treatment beyond third-line therapy for HER2-positive (HER2+) metastatic breast cancer, considering factors such as prior therapies, residual toxicities, and patient preferences when selecting from multiple options.